Petros Pharmaceuticals Inc. (PTPI)
OTC PINK OTC PINK Primary Summary
PTPI Chart
Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules
Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces its conducive position in connection with the recently issued final rule, "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" ("ACNU") by the United States Food and Drug Administration (the "FDA") for companies seeking Rx-to-OTC switch for pharmaceutical products. The Company's recently announced shift in its primary business strategy was initially developed under guidance of earlier iterations of the rule, and the Company believes the final rule will help facilitate the development of its Software as a Medical Device (SaMD) concept, which is designed to serve the emerging self-care market.
Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”
Company positions itself for new innovation utilizing AI and quantum computing to help expand patient access to drugs via OTC access NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announced that in a recent podcast, The Intelligent Leadership Podcast, titled, "The New Era of Healthcare, AI, Data and Consumer Empowerment," Petros President Fady Boctor discussed the Company's concerted efforts to develop its proprietary platform as a prospective technology driven Rx-to-OTC switch solution across a multitude of conditions and existing Rx only therapies. During the podcast, Boctor discussed Petros' technology tool development around a Drug Facts Label to self-select, as well as the utilization of AI to ensure safe engagement and access to a drug that has made the Rx-to-OTC switch.
Petros Pharmaceuticals Inc. (PTPI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Petros Pharmaceuticals Inc. ever had a stock split?
Petros Pharmaceuticals Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Fady Boctor CEO | OTC PINK Exchange | 71678J308 CUSIP |
| US Country | 3 Employees | - Last Dividend | 1 May 2025 Last Split | 2 Dec 2020 IPO Date |
Overview
Petros Pharmaceuticals, Inc. is a prominent pharmaceutical company with a dedicated focus on men's health therapeutics both in the United States and internationally. The company operates through two main segments: Prescription Medications and Medical Devices, leveraging its expertise to pioneer treatments for conditions impacting men's health. Based in New York, New York, Petros Pharmaceuticals is committed to the commercialization and development of innovative therapeutic solutions, aiming to address various aspects of men’s health with a significant focus on erectile dysfunction (ED) and Peyronie’s disease.
Products and Services
- Stendra
Stendra is a prescription medication that Petros Pharmaceuticals commercializes as a PDE-5 inhibitor for the treatment of erectile dysfunction (ED). This innovative product stands out by providing an effective treatment option for ED, showcasing the company's commitment to addressing and enhancing men's sexual health.
- H100
A novel and patented topical formulation candidate, H100 is under development for the treatment of acute Peyronie's disease. This therapeutic solution represents the company's focus on pioneering treatments for conditions affecting men’s sexual health, providing hope for those suffering from this distressing condition.
- Vacuum Erection Devices
Petals Pharmaceuticals offers vacuum erection devices as a non-invasive treatment option for erectile dysfunction. These devices are a testament to the company’s dedication to providing a range of therapeutic solutions to support men’s health and wellbeing.
- PreBoost
PreBoost is a product designed for the treatment of premature ejaculation, offering men a practical solution to enhance their sexual health and performance. This product aligns with Petros Pharmaceuticals' mission to address a comprehensive spectrum of men's sexual health issues.
- VenoSeal
VenoSeal is another innovative offering by Petros Pharmaceuticals, aimed at treating venous leak-related erectile dysfunction. It embodies the company's effort to tackle various underlying causes of ED, providing customized solutions to patients.
- Penile Injections
For men seeking a direct approach to treating erectile dysfunction, Petros Pharmaceuticals provides penile injections. This method offers an effective, albeit more invasive, alternative for those who may not respond to oral medications.
- Urinary Tract Infection Tests
Understanding the importance of comprehensive men's health, the company also offers urinary tract infection tests. These tests are crucial in diagnosing and treating infections promptly, preventing further complications and ensuring overall urinary tract health.
